Netarsudil mesylate is under clinical development by Alcon and currently in Phase III for Fuchs Endothelial Corneal Dystrophy (FECD). According to GlobalData, Phase III drugs for Fuchs Endothelial Corneal Dystrophy (FECD) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Netarsudil mesylate LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Netarsudil mesylate overview

Netarsudil mesylate (Rhopressa, Rhokiinsa) acts as an Antiglaucomas agent. It is formulated as drops solution for ophthalmic route of administration. It is indicated for the reduction of elevated intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension.

The drug candidate is under development for the treatment of corneal edema associated with Fuchs Dystrophy, ocular hypertension and open-angle glaucoma.

Alcon overview

Alcon is engaged in the development and manufacturing of devices in the field of ophthalmology. The company’s portfolio encompasses contact lenses and surgical products, including implantables, consumables and surgical equipment. The company’s products are indicated for the treatment of various conditions such as cataracts, glaucoma, retinal diseases and refractive errors. It conducts clinical trials to evaluate the safety and efficacy of its products for prevention and cure of blindness and different eye diseases. Alcon’s pipeline products are developed through collaboration with institutions, medical innovators, research advisors and academic thought leaders. The company has operations in the Americas, Europe, the Middle East, and Africa and Asia Pacific. Alcon is headquartered in Geneva, Switzerland.

For a complete picture of Netarsudil mesylate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.